Independent advisory for early-stage biotech founders — combining clinical medicine, biomedical engineering, and hands-on program management to move programs from concept to clinic without losing time or investor confidence.
Ask most people where medtech projects get stuck, and they'll say regulation — FDA pathways, clinical trials, compliance. That's real, but it's rarely where things actually stall first.
In our experience, the harder barrier comes earlier: the space between having an idea and actually attempting to make it real. The overthinking. The what-ifs. The fear of taking a step you can't take back.
That's the gap Arakotis exists to close — not just with a plan, but with the encouragement and support to move through the uncertainty and actually start.
Arakotis was founded to close a gap most biotech startups feel early: brilliant science without the clinical framing, regulatory foresight, or program discipline to get it funded and built.
The firm is led by a founder trained as a physician and biomedical engineer, with hands-on project management experience running complex, cross-functional programs.
Read the full story →Mapping the pathway to FDA (or equivalent) submission, framing clinical evidence needs early.
Turning bench-stage science into a staged, fundable development plan.
Hands-on management of R&D and trial timelines, vendor coordination, and teams.
For founders and companies bringing a medical technology idea to market — from early feasibility through regulatory strategy, product development, and go-to-market planning. Five engagement tiers, from a single working session to ongoing hands-on support.
See entrepreneur servicesFor students with a medical, biotech, or engineering idea they're not sure what to do with yet — special reduced rates across every tier, and a free consultation to talk through scope and feasibility.
See student ratesFor entrepreneurs and companies looking to collaborate directly rather than engage as a client — equity, joint ventures, or other arrangements negotiated case by case with the founder and CEO.
Explore partnershipsMost first conversations are free — a chance to see whether an outside clinical and technical read is useful before anything is signed.
Contact us